Irodalom:
1. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ.: Adjuvant chemotherapy versus
observation in patients with colorectal cancer: a randomised study. Quaasar Collaborative Group,
Lancet 2007 Dec 15;370(9604):2020-9. Comment in: Lancet. 2007 Dec 15;370(9604):1980-1.
2. Wilson KS, Fitzgerald CA, Barnett JB, Gill S, Khoo KE.: Adjuvant therapy with raltitrexed in patients
with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer
Invest. 2007 Dec;25(8):711-4.
3. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G.:
Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy:
does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation
for Research and Treatment of Cancer Radiation Oncology Group. European Organisation for Research
and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007 Oct 1;25(28):4379-86.
Comment in: J Clin Oncol. 2007 Oct 1;25(28):4339-40.
4. André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N,
Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.: Phase III study
comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment
for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007 Aug
20;25(24):3732-8.
5. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP,
Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ,
Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N.: Oxaliplatin combined with weekly bolus
fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results
from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30. Comment in: J Clin
Oncol. 2007 Jun 1;25(16):2156-8.
6. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E,
Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG.: Phase
III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety
analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9.
7. Parks R, Gonen M, Kemeny N, Jarnagin W, D’Angelica M, DeMatteo R, Garden OJ, Blumgart LH, Fong Y.:
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of
data from two continents. J Am Coll Surg. 2007 May;204(5):753-61; discussion 761-3. Epub 2007 Feb 23.
8. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M.: Outcome
after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy.
Ann Surg Oncol. 2007 Mar;14(3):1151-60. Epub 2006 Dec 31.
A vastagbél 281
9. Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H.: Cetuximab in combination with
5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially
unresectable colorectal liver metastases. Onkologie. 2007 Dec;30(12):637-43. Epub 2007 Nov 30.
10. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D,
Ducreux M, Castagne V, Azoulay D, Castaing D.: Hepatic resection after rescue cetuximab treatment
for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol.
2007 Oct 10;25(29):4593-602.
11. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F,
Portier G, Nordlinger B.: Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin
(FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Cancer Chemother Pharmacol. 2007 Sep 28 [Epub ahead of print]
12. Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D’Argento E, Trigila N, Astone A,
Pozzo C.: Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus
folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007 Oct 22;
97(8):1035-9. Epub 2007 Sep 25.
13. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato
A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G:
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic
colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer.
2007 Sep;43(14):2037-45. Epub 2007 Sep 4.
14. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM.: Addition of bevacizumab
to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity
after resection of colorectal liver metastases. J Am Coll Surg. 2008 Jan;206(1):96-106. Epub 2007 Sep 17.
15. D’Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart
LH, Saltz LB.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use
of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007 Feb;14(2):759-65. Epub 2006 Nov 11.
16. Ceelen W, Boterberg T, Pattyn P, van Eijkeren M, Gillardin JM, Demetter P, Smeets P, Van Damme N,
Monsaert E, Peeters M.: Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy
in locally advanced rectal cancer. Ann Surg Oncol. 2007 Feb;14(2):424-31. Epub 2006 Nov 10.
17. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA.: Preoperative chemotherapy for
colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg.
2007 Jul;11(7):860-8.
18. Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D.:Preoperative radiotherapy
combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer.
2007 Nov 19;97(10):1333-7. Epub 2007 Nov 6.
19. Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK,
Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR: Impact of complete response to
chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Pitot
HC 4th, Goldberg RM J Clin Oncol. 2007 Aug 10;25(23):3469-74. Erratum in: J Clin Oncol. 2007 Nov
20;25(33):5339.
20. Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D,
Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A.:First-line single-agent cetuximab in patients
with advanced colorectal cancer. Ann Oncol. 2007 Dec 10 [Epub ahead of print]
21. E. Van Cutsem, G. Bodoky, J. Kyung Roh, G. Folprecht, Y.S. Park, J.L. Van Laethem, J.L. Raoul, F. Ciardiello,
P. Lebrun, P. Rougier: CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs.
FOLFIRI in first-line metastatic colorectal cancer (mCRC). European Journal of Cancer Supplements,
Vol 5 No 4, Page 235.
282 Gastro Update 2008
22. Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P,
Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A.: Phase II trial of
cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 2007 Nov 20;25(33):5225-32.
23. Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Lorizzo K, Santoro L,
Boselli S, de Braud F.: First clinical experience of orally active epidermal growth factor receptor inhibitor
combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer.
2007 Aug 15;110(4):752-8.
24. Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D,Bodoky G, Van Hazel G,
Salek T, Wolf M, Devercelli G, Woolley M, Amado RG.: Association of progression-free survival with
patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J
Cancer. 2007 Dec 3;97(11):1469-74.
25. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A,
Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M.: An open-label, single-arm study assessing
safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard
chemotherapy. Ann Oncol. 2008 Jan;19(1):92-8. Epub 2007 Sep 4.
26. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ.:
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer.
2007 Sep 1;110(5):980-8.
27. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J,
Richardson G, Wolf M, Amado RG.: Open-label phase III trial of panitumumab plus best supportive care
compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal
cancer. J Clin Oncol. 2007 May 1;25(13):1658-64. Comment in: J Clin Oncol. 2007 May 1;25(13):
1639-41. J Clin Oncol. 2007 Oct 10;25(29):4691-2; author reply 4692.
28. Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR.:Panitumumab
with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin
Colorectal Cancer. 2007 Mar;6(6):427-32.
29. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X,
Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J,
Clark EA, Mauro DJ.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease
control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007 Aug
1;25(22):3230-7.
30. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R,
Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T.: Clinical relevance of
KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Br J Cancer. 2007 Apr 23;96(8):1166-9. Epub 2007 Mar 20.
31. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA,
Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200.: Bevacizumab in combination
with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal
cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr
20;25(12):1539-44.
32. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L,
Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulias V, Mavroudis D,
Souglakos J.: Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil
(FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer.
2007 May 30;7:91.
33. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC,
Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ.: Phase II trial of sunitinib
A vastagbél 283
in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct
20;25(30):4793-9.
34. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ,
Battu S, Lawrence C, Ryan DP.: Phase II study of FOLFOX, bevacizumab and erlotinib as first-line
therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul;18(7):1185-9.
35. Gelibter AJ, Gamucci T, Pollera CF, Di Costanzo F, Nuzzo C, Gabriele A, Signorelli C, Gasperoni S,
Ferraresi V, Giannarelli D, Cognetti F, Zeuli M.: A phase II trial of gefitinib in combination with
capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Curr Med Res Opin. 2007 Sep;23(9):2117-23.
36. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G,
Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T,
Tabah-Fisch I, Tournigand C.: Reintroduction of oxaliplatin is associated with improved survival in
advanced colorectal cancer. J Clin Oncol. 2007 Aug 1;25(22):3224-9. Comment in: J Clin Oncol. 2007
Aug 1;25(22):3191-3.
37. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S,
Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ.: Different
strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal
cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007 Jul 14;370(9582):143-52. Erratum
in: Lancet. 2007 Aug 18;370(9587):566. Comment in: Lancet. 2007 Jul 14;370(9582):105-7.
38. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ,
Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ,
Mol L, Dalesio O, Punt CJ.: Sequential versus combination chemotherapy with capecitabine, irinotecan,
and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet.
2007 Jul 14;370(9582):135-42. Comment in: Lancet. 2007 Jul 14;370(9582):105-7.
39. Schmoll HJ, Sargent D.: Single agent fluorouracil for first-line treatment of advanced colorectal cancer
as standard? Lancet. 2007 Jul 14;370(9582):105-7. Erratum in: Lancet. 2008 Dec 22;370(9605):2102.
Comment in: Lancet. 2007 Dec 8;370(9603):1904-5; author reply 1905. Comment on: Lancet. 2007 Jul
14;370(9582):135-42. Lancet. 2007 Jul 14;370(9582):143-52.
40. André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M, Postel Vinay S,
Bidard FC, Louvet C, de Gramont A; GERCOR (French Oncology Research Group).: Phase II study of
an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal
cancer: a GERCOR study. Ann Oncol. 2007 Jan;18(1):77-81. Epub 2006 Oct 9.
41. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W,
Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C,
Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest.: Phase III trial of infusional fluorouracil,
leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin,
and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico
Nord Ovest. J Clin Oncol. 2007 May 1;25(13):1670-6.
42. Bécouarn Y, Senesse P, Thézenas S, Boucher E, Adenis A, Cany L, Jacob JH, Cvitkovic F, Montoto-Grillot C,
Ychou M; Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.:
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen
(irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin)
in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des
Centres de Lutte Contre le Cancer. Ann Oncol. 2007 Dec;18(12):2000-5. Epub 2007 Sep 4.
43. Maniadakis N, Pallis A, Fragoulakis V, Prezerakos P, Georgoulias V.: of a multicentre, randomised,
phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in
Greece. Curr Med Res Opin. 2007 Sep;23(9):2251-7. The role of a drug holiday: revisited. Chu E. Clin
Colorectal Cancer. 2007 Jul;6(8):554-5.
284 Gastro Update 2008
44. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey
A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group: Phase III study of capecitabine
plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:
a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007 Sep 20;25(27): 4217-23. Epub
2007 Jun 4. Comment in: J Clin Oncol. 2007 Nov 1;25(31):5041-2; author reply 5042-3. J Clin Oncol.
2007 Nov 1;25(31):5043-5; author reply 5045-6. J Clin Oncol. 2007 Sep 20;25(27):4165-7.
45. Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt
B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E: Phase III study of
capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line
therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment
of Digestive Tumors Trial. Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J
Clin Oncol. 2007 Sep 20;25(27):4224-30. Epub 2007 Jun 4. Comment in: J Clin Oncol. 2007 Nov 1;25
(31):5043-5; author reply 5045-6. J Clin Oncol. 2007 Sep 20;25(27):4165-7.
46. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis
AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V.: Phase II trial
of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer
who progressed after oxaliplatin-based chemotherapy. Ann Oncol. 2007 Feb;18(2):305-10. Epub
2006 Nov 1.
47. Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR,
Bexon A, Lin E.: Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy
for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007 Aug;30(4):350-7.
48. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A,
Pusceddu S.: Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in
first-line treatment of metastatic colorectal cancer. Ann Oncol. 2007 Nov;18(11):1810-6. Epub 2007 Sep 6.
49. Mocellin S, Pilati P, Lise M, Nitti D.: Meta-analysis of hepatic arterial infusion for unresectable liver
metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007 Dec 10;25(35):5649-54.
50. Gallagher DJ, Capanu M, Raggio G, Kemeny N.: Hepatic arterial infusion plus systemic irinotecan in
patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic
oxaliplatin: a retrospective analysis. Ann Oncol. 2007 Dec;18(12):1995-9. Epub 2007 Oct 24.
51. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M.:
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from
colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008 Jan;15(1):219-26. Epub
2007 Sep 26.
52. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van Cutsem E.: Magnesium
wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a
prospective study. Lancet Oncol. 2007 May;8(5):387-94. Comment in: Lancet Oncol. 2007 May;8 (5):366-7.
53. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE,
Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O’Connell MJ,
Costantino JP, Wolmark N.: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil
and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J
Clin Oncol. 2007 Jun 1;25(16):2205-11. Epub 2007 Apr 30. Comment in: J Clin Oncol. 2007 Jun 1;
25(16):2156-8.
54. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M,
Francini G.: Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer:
a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008 Jan;
61(1):105-11. Epub 2007 Apr 12.
55. des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, Le Toumelin P, Uzzan B,
Perret GY, Morere JF, Breau JL, Fagard R, Schischmanoff PO.: Microsatellite instability and sensitivitiy
A vastagbél 285
to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2715-9.
Erratum in: Anticancer Res. 2007 Sep-Oct;27(5b):3667.
56. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ.: Prognostic and predictive
roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National
Surgical Adjuvant Breast and Bowel Project Collaborative Study. National Cancer Institute. J Clin Oncol.
2007 Mar 1;25(7):767-72. Epub 2007 Jan 16. Comment in: J Clin Oncol. 2007 Mar 1;25(7):754-6.
57. Lamberti C, Lundin S, Bogdanow M, Pagenstecher C, Friedrichs N, Büttner R, Sauerbruch T.:
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Int J Colorectal Dis. 2007 Feb;22(2):145-52. Epub 2006 May 25.
58. Tang PA, Bentzen SM, Chen EX, Siu LL.: Surrogate end points for median overall survival in metastatic
colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
J Clin Oncol. 2007 Oct 10;25(29):4562-8. Epub 2007 Sep 17.
59. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P.:
Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007
Nov 20;25(33):5218-24. Comment in: J Clin Oncol. 2007 Nov 20;25(33):5153-4.
60. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF,
O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Kerr D, Green E, Wieand HS,
Goldberg RM, de Gramont A.: End points for colon cancer adjuvant trials: observations and recommendations
based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the
ACCENT Group. ACCENT Group. J Clin Oncol. 2007 Oct 10;25(29):4569-74. Epub 2007 Sep 17.
61. Punt CJ, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, Påhlman L, Sobrero A, Douillard
JY.: Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed
definitions for future trials. J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003. Epub 2007 Jun 27.
62. Sorbye H, Köhne CH, Sargent DJ, Glimelius B.: Patient characteristics and stratification in medical
treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic
reporting and stratification. Ann Oncol. 2007 Oct;18(10):1666-72. Epub 2007 Jul 28.
63. O’Dwyer P.J.,Eckhardt S.G., Haller D.G, Tepper J., Ahnen D., Hamilton S., Benson, A. B.: Gastrointestinal
Scientific Leadership Council of the Coalition of Cancer Cooperative Groups : Priorities in colorectal
cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the
Coalition of Cancer Cooperative Groups. Journal of clinical oncology, 25 (16), p.2313-2321, Jun 2007.
64. Burch J.A.Soares-Weiser K., St John D.B.,Duffy S.,Smith S.,Kleijnen J., Westwood M.: Diagnostic accuracy
of faecal occult blood tests used in screening for colorectal cancer: a systematic review. Journal of medical
screening, 14 (3), p.132-137, Jan 2007.
65. Segnan N., Senore C., Andreoni B., Azzoni A., Bisanti L., Cardelli A., Castiglione G.: SCORE3 Working
Group-Italy: Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for
colorectal cancer screening. Gastroenterology, 132 (7), p.2304-2312, Jun 2007
66. Lin O.S., Kozarek R.A., Schembre D. B., Ayub K., Gluck M.,Cantone N., Soon M -S., Dominitz J. A.: Risk
stratification for colon neoplasia: screening strategies using colonoscopy and computerized tomographic
colonography. Gastroenterology, 131 (4), p.1011-1019, Oct 2006.
67. Pickhardt P.J., Hassan C., Laghi A., Zullo. A., Kim D.H., Morini, S: Cost-effectiveness of colorectal
cancer screening with computed tomography colonography: the impact of not reporting diminutive
lesions. Cancer, 109 (11), p.2213-2221, Jun 2007.
